Abstract
Antivascular approaches aim to cause rapid and catastrophic shutdown in the vascular function of the tumour, leading to extensive tumour cell death. Tumour vascular disrupting agents (VDAs) are a new class of cancer therapies that target the existing vasculature of tumours, taking advantage of the relative instability of tumour vasculature and its supporting structures. Treatment with VDAs induces a rapid collapse and regression of tumour vessels, with a consequent deprivation of blood and oxygen which leads to ischemic or hemorrhagic necrosis of the tumour. In this review, an overview of the most recently developed vascular disrupting agents is reported, focusing on the biological effects exerted by these compounds on endothelial cells and tumour vasculature, potentially effective in the treatment of several malignancies including upper gastrointestinal tumours. In particular, we have focused on the antimitotic agent combretastatin and its numerous synthetic analogues such as combretastatin A-4-phosphate, OXI4503, and AVE8062, and on the colchicine analogue ZD6126.
| Original language | English |
|---|---|
| Pages (from-to) | 1039-1049 |
| Number of pages | 11 |
| Journal | Current Medicinal Chemistry |
| Volume | 21 |
| Issue number | 8 |
| DOIs | |
| Publication status | Published - 2014 |
Fingerprint
Keywords
- Gastrointestinal cancers
- Upper gastrointestinal malignancies
- Vascular disrupting agents
ASJC Scopus subject areas
- Molecular Medicine
- Pharmacology
Cite this
New vascular disrupting agents in upper gastrointestinal malignancies. / Quatrale, A. E.; Porcelli, L.; Gnoni, A.; Numico, G.; Paradiso, A.; Azzariti, A.
In: Current Medicinal Chemistry, Vol. 21, No. 8, 2014, p. 1039-1049.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - New vascular disrupting agents in upper gastrointestinal malignancies
AU - Quatrale, A. E.
AU - Porcelli, L.
AU - Gnoni, A.
AU - Numico, G.
AU - Paradiso, A.
AU - Azzariti, A.
PY - 2014
Y1 - 2014
N2 - Antivascular approaches aim to cause rapid and catastrophic shutdown in the vascular function of the tumour, leading to extensive tumour cell death. Tumour vascular disrupting agents (VDAs) are a new class of cancer therapies that target the existing vasculature of tumours, taking advantage of the relative instability of tumour vasculature and its supporting structures. Treatment with VDAs induces a rapid collapse and regression of tumour vessels, with a consequent deprivation of blood and oxygen which leads to ischemic or hemorrhagic necrosis of the tumour. In this review, an overview of the most recently developed vascular disrupting agents is reported, focusing on the biological effects exerted by these compounds on endothelial cells and tumour vasculature, potentially effective in the treatment of several malignancies including upper gastrointestinal tumours. In particular, we have focused on the antimitotic agent combretastatin and its numerous synthetic analogues such as combretastatin A-4-phosphate, OXI4503, and AVE8062, and on the colchicine analogue ZD6126.
AB - Antivascular approaches aim to cause rapid and catastrophic shutdown in the vascular function of the tumour, leading to extensive tumour cell death. Tumour vascular disrupting agents (VDAs) are a new class of cancer therapies that target the existing vasculature of tumours, taking advantage of the relative instability of tumour vasculature and its supporting structures. Treatment with VDAs induces a rapid collapse and regression of tumour vessels, with a consequent deprivation of blood and oxygen which leads to ischemic or hemorrhagic necrosis of the tumour. In this review, an overview of the most recently developed vascular disrupting agents is reported, focusing on the biological effects exerted by these compounds on endothelial cells and tumour vasculature, potentially effective in the treatment of several malignancies including upper gastrointestinal tumours. In particular, we have focused on the antimitotic agent combretastatin and its numerous synthetic analogues such as combretastatin A-4-phosphate, OXI4503, and AVE8062, and on the colchicine analogue ZD6126.
KW - Gastrointestinal cancers
KW - Upper gastrointestinal malignancies
KW - Vascular disrupting agents
UR - http://www.scopus.com/inward/record.url?scp=84896373454&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84896373454&partnerID=8YFLogxK
U2 - 10.2174/09298673113209990233
DO - 10.2174/09298673113209990233
M3 - Article
C2 - 23992324
AN - SCOPUS:84896373454
VL - 21
SP - 1039
EP - 1049
JO - Current Medicinal Chemistry
JF - Current Medicinal Chemistry
SN - 0929-8673
IS - 8
ER -